HALO's Q4 Earnings Beat, Higher Royalties Drive Revenue Growth

Halozyme Therapeutics (HALO) reported fourth-quarter 2024 adjusted earnings of $1.26 per share, which beat the Zacks Consensus Estimate of$1.16. The company had recorded adjusted earnings of 82 cents per share in the year-ago period.See the Zacks Earnings Calendar to stay ahead of market-making news.Total revenues in the fourth quarter increased 30% year over year to $298 million. Revenues surpassed the Zacks Consensus Estimate of$284 million.The top-line growth was primarily driven by higher royalty paym ...